Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of alemtuzumab as second-line therapy in mantle cell lymphoma
2004-003516-35Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Dec 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in mantle cell lymphoma (MCL), sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Started Dec 2005; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2004-003516-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003516-35.